Method of diagnosing, monitoring, staging, imaging and treating prostate cancer

1. A method for diagnosing the presence of prostate cancer in a patient comprising:

(a) determining levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues or bodily fluids in a patient; and

(b) comparing the determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3, with levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in said patient versus normal human control is associated with the presence of prostate cancer.

2. A method of diagnosing metastases of prostate cancer in a patient comprising:

(a) identifying a patient having prostate cancer that is not known to have metastasized;

(b) determining levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues, or bodily fluid from said patient; and

(c) comparing the determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 with levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in the patient versus the normal human control is associated with a cancer which has metastasized.

3. A method of staging prostate cancer in a patient having prostate cancer comprising:

(a) identifying a patient having prostate cancer;

(b) determining levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissue, or bodily fluid from said patient; and

(c) comparing determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 with levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 is associated with a cancer which is regressing or in remission.

4. A method of monitoring prostate cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having prostate that is not known to have metastasized;

(b) periodically determining levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined levels with levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in the patient versus the normal human control is associated with a cancer which has metastasized.

5. A method of monitoring a change in stage of prostate cancer in a patient comprising:

(a) identifying a patient having prostate cancer;

(b) periodically determining levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 with levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined levels of polynucleotide comprising SEQ ID NO: 3, native protein expressed by the gene comprising polynucleotide comprising SEQ ID NO: 3, or native mRNA encoded by the gene comprising polynucleotide comprising SEQ ID NO: 3 in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.